HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.

AbstractAIMS:
Rivaroxaban reduces cardiovascular death, myocardial infarction (MI), or stroke in patients following acute coronary syndrome (ACS). We aimed to characterize the specific effects of rivaroxaban on the size and type of MI.
METHODS:
The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) study randomized 15,526 patients with a recent ACS to rivaroxaban 2.5 mg BID, rivaroxaban 5 mg BID, or placebo. An independent clinical events committee adjudicated each MI that occurred during the study and further classified them based on type. Data are presented as two-year Kaplan-Meier event rates and hazard ratios (HRs) and 95% confidence intervals (CI).
RESULTS:
In total, 665 patients experienced a post-randomization MI. The majority (n=535, 80.5%) were spontaneous (Type 1) events. Rivaroxaban reduced spontaneous MI when compared with placebo (4.4% vs 5.7%, HR 0.80, 95% 0.67-0.95, p=0.01), and there were directionally consistent reductions with both the 2.5 mg BID (4.7% vs 5.7%, HR 0.84, 95% 0.68-1.02, p=0.08) and 5 mg BID doses (4.1% vs 5.7%, HR 0.77, 95% 0.62-0.94, p=0.01) as compared with placebo. Rivaroxaban reduced MI with large elevations in troponin or creatine kinase-MB (CK-MB) fraction (1.8% vs 2.4%, HR 0.73, 95% CI 0.56-0.96, p=0.03) and STEMI events (1.7% vs 2.5%, HR 0.74, 95% CI 0.56-0.99, p=0.04).
CONCLUSIONS:
In patients stabilized and followed after ACS, the majority of MIs that occur are spontaneous and rivaroxaban significantly reduced the incidence of these events. Notably, rivaroxaban reduced MIs with extensive biomarker release and ST-segment elevation.
AuthorsMatthew A Cavender, C Michael Gibson, Eugene Braunwald, Stephen D Wiviott, Sabina A Murphy, Eri Toda Kato, Alexei N Plotnikov, Marcos Amuchástegui, Ton Oude Ophuis, Maarten van Hessen, Jessica L Mega
JournalEuropean heart journal. Acute cardiovascular care (Eur Heart J Acute Cardiovasc Care) Vol. 4 Issue 5 Pg. 468-74 (Oct 2015) ISSN: 2048-8734 [Electronic] England
PMID25318481 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© The European Society of Cardiology 2014.
Chemical References
  • Biomarkers
  • Factor Xa Inhibitors
  • Troponin
  • Rivaroxaban
  • Creatine Kinase, MB Form
Topics
  • Acute Coronary Syndrome (drug therapy, metabolism, pathology)
  • Biomarkers (metabolism)
  • Creatine Kinase, MB Form (metabolism)
  • Drug Administration Schedule
  • Factor Xa Inhibitors (administration & dosage)
  • Humans
  • Middle Aged
  • Myocardial Infarction (diagnosis, drug therapy, metabolism, prevention & control)
  • Rivaroxaban (administration & dosage)
  • Secondary Prevention
  • Thrombolytic Therapy (methods)
  • Treatment Outcome
  • Troponin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: